$4.37
0.46% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
CA27966L1085
Symbol
EDSA
Sector
Industry

Edesa Biotech Inc Stock price

$4.37
-0.53 10.82% 1M
+0.06 1.27% 6M
-0.20 4.38% YTD
-1.58 26.56% 1Y
-36.23 89.24% 3Y
-32.03 87.99% 5Y
-5,081.83 99.91% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.02 0.46%
ISIN
CA27966L1085
Symbol
EDSA
Sector
Industry

Key metrics

Market capitalization $14.19m
Enterprise Value $12.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.95
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.38m
Free Cash Flow (TTM) Free Cash Flow $-5.38m
Cash position $2.04m
EPS (TTM) EPS $-1.72
P/E forward negative
Short interest 0.60%
Show more

Is Edesa Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Edesa Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Edesa Biotech Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Edesa Biotech Inc:

Buy
100%

Financial data from Edesa Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.19 0.19
12% 12%
-
-0.19 -0.19
12% 12%
-
- Selling and Administrative Expenses 4.27 4.27
15% 15%
-
- Research and Development Expense 3.73 3.73
34% 34%
-
-8.19 -8.19
14% 14%
-
- Depreciation and Amortization 0.19 0.19
12% 12%
-
EBIT (Operating Income) EBIT -8.38 -8.38
14% 14%
-
Net Profit -6.93 -6.93
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Edesa Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edesa Biotech Inc Stock News

Neutral
GlobeNewsWire
29 days ago
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business.
Neutral
Accesswire
3 months ago
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.
Neutral
Accesswire
4 months ago
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business. During the quarter, the company expanded site selection activities for ...
More Edesa Biotech Inc News

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.

Head office Canada
CEO Pardeep Nijhawan
Employees 16
Founded 2007
Website www.edesabiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today